The therapeutic potential of GLP-1R and its agonists has reshaped approaches to managing type 2 diabetes mellitus (T2DM), cardiovascular diseases, obesity, and even neurodegenerative conditions. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.